Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab
This study is currently recruiting participants.
Verified September 2012 by The Cleveland Clinic
Sponsor:
The Cleveland Clinic
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT01617148
First received: June 8, 2012
Last updated: September 4, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |